At a Glance
- Company: Rentschler Biopharma SE
- Location: Laupheim, Germany (HQ); Milford, USA
- Headline figures: Interim CEO appointment effective immediately
- Focus area: CDMO for biopharmaceuticals (mAbs, gene therapy)
- Next steps: Permanent CEO search; COO successor announcement
What happened?
Rentschler Biopharma announced Executive Board changes on 19 January 2026, with CEO Benedikt von Braunmuehl stepping down by mutual agreement with the Supervisory Board. Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, was appointed interim CEO effective immediately to maintain operational continuity during the leadership transition.
Why does it matter?
The move supports Rentschler’s next growth phase, building on recent capacity expansions and efficiency gains amid strong CDMO demand for biologics manufacturing. Buecheler’s deep industry experience ensures stability for clients during a competitive market for contract services.
Who’s behind it?
Rentschler Biopharma, a family-owned CDMO, provides process development and GMP manufacturing across four sites. Buecheler brings 30+ years from Boehringer Ingelheim, including SVP Biopharmaceuticals.
How was it achieved?
Supervisory Board selected Buecheler for his strategic involvement and track record in operations, regulatory approvals and expansions; coincides with COO Christiane Bardroff’s planned Q1 departure.
What’s next?
Interim leadership drives client-focused expansion and value creation; permanent CEO and COO to be named soon.
What are people saying?
Nikolaus F. Rentschler, Chairman: “Buecheler… has many years of international leadership experience.” Buecheler: “Rentschler Biopharma is currently in a strong operational and economic position.”